Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Strensiq Market Growth Potential: How Will Market Size Change Through 2030?
Growth during the historic period was driven by several key factors, including better identification of hypophosphatasia cases, the presence of orphan drug incentives, proven effectiveness of enzyme replacement therapies through clinical studies, broader genetic testing initiatives, and heightened awareness among healthcare professionals.
Growth during the forecast period results from greater acceptance of treatments among adult-onset HPP patients, improved access to therapies for rare diseases, heightened funding for orphan drug development, a stronger emphasis on administering care at home, and ongoing advances in customized treatment strategies. Key developments shaping this period include a heightened commitment to enzyme replacement therapies, higher detection frequencies for uncommon bone conditions, broader implementation of extended treatment regimens, increased adoption of subcutaneous delivery methods, and strengthened systems for patient tracking and compliance support.
Download A Free Sample Report For Comprehensive Market Insights:
Strensiq Market Expansion Supported By Key Demand Factors
The growing emphasis on treating rare diseases is anticipated to drive the expansion of the Strensiq market in the coming period. Rare disease treatment encompasses medical interventions tailored for conditions affecting a limited segment of the population, frequently involving specialized therapies or medications with restricted availability. This heightened focus stems from advancements in precision medicine, unmet patient needs, expanding regulatory incentives, and prospects for healthcare innovation. Strensiq, an enzyme replacement therapy, is critical for managing hypophosphatasia—a rare genetic disorder impairing bone mineralization—by restoring the deficient alkaline phosphatase enzyme, thus enhancing bone health, reducing skeletal deformities, and improving quality of life for affected individuals. For example, as reported by the Cystic Fibrosis Trust, a UK-based non-profit, in October 2024, the number of CF-registered individuals in the UK exceeded 11,318 in 2023. Additionally, 63.7% of the UK CF population are over 16, and 16.7% are over 40. Consequently, the intensified focus on rare disease treatment is fueling Strensiq market growth.
The rise of personalized medicine is expected to accelerate Strensiq market growth moving forward. Personalized medicine is an approach that customizes healthcare strategies and treatments based on each patient’s distinct characteristics. This field is expanding because it tailors therapies to an individual’s genetic makeup, lifestyle, and environment, boosting treatment efficacy while reducing adverse effects. Strensiq contributes to personalized medicine by delivering targeted enzyme replacement therapy for hypophosphatasia, a rare genetic disorder, facilitating customized treatment plans that account for specific genetic mutations and varying disease severity, thereby enhancing patient outcomes and life quality. For instance, in February 2024, the Personalized Medicine Coalition, a US-based advocacy group, noted that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from six in 2022. Thus, the growing adoption of personalized medicine is driving Strensiq market expansion.
Increased healthcare spending is projected to drive the Strensiq market’s growth in the future. Health expenditures cover all costs related to delivering health services, family planning, nutrition programs, and emergency health-focused aid. Healthcare spending is escalating as more stakeholders prioritize advanced therapies and superior patient outcomes, leading to greater investment in specialized medical care. Strensiq is instrumental in this trend by offering enzyme replacement therapy for hypophosphatasia, improving patient results, and boosting demand for specialized treatments. As an example, in May 2023, the UK-based Office for National Statistics reported that healthcare expenditure in the UK reached approximately $362.08 billion (£292 billion) in 2023, a nominal increase of 5.6%. Furthermore, healthcare spending as a percentage of GDP dipped slightly to 10.9% in 2023 from 11.1% in 2022. Consequently, rising healthcare expenditures are propelling the Strensiq market forward.
Strensiq Market Segmentation Trends And Revenue Drivers
The strensiq market covered in this report is segmented –
1) By Formulation: Subcutaneous Injection, Single-Use Vials
2) By Clinical Indication: Perinatal Or Neonatal-Onset HPP, Infantile-Onset HPP, Childhood-Onset HPP, Adult-Onset HPP
3) By Distribution Channel: Retail Pharmacies, Online Pharmacies
4) By End User: Pediatric, Adult
Strensiq Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the strensiq market are AstraZeneca plc
Access The Complete Strensiq Market Report:
Strensiq Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the strensiq market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the strensiq market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model